{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:00:50Z","timestamp":1761166850234,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pupt.2023.102280","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:39:35Z","timestamp":1701866375000},"page":"102280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effects of nirmatrelvir\/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-5265","authenticated-orcid":false,"given":"Xiaoxing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianbo","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2023.102280_bib1","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1111\/ajt.16692","article-title":"COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: a comparative analysis from a multicenter study","volume":"21","author":"Heldman","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2023.06.007","article-title":"COVID-19 in hospitalized solid organ transplant recipients in a nationwide registry study","volume":"134","author":"Moreno-Torres","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.pupt.2023.102280_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13665-023-00302-3","article-title":"Current and emerging therapies for COVID-19 in lung transplantation","volume":"12","author":"Friedman","year":"2023","journal-title":"Curr Pulmonol Rep"},{"key":"10.1016\/j.pupt.2023.102280_bib4","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1097\/TP.0000000000004371","article-title":"Risk factors, and outcomes of COVID-19 infection in a large cohort of solid organ transplant recipients","volume":"106","author":"Sahota","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.pupt.2023.102280_bib5","first-page":"ciac724","article-title":"Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2023.102280_bib6","first-page":"1","article-title":"Diagnosis and treatment plan for COVID-19 (trial version 10)","volume":"16","year":"2023","journal-title":"Chinese Journal of Clinical Infectious Diseases"},{"key":"10.1016\/j.pupt.2023.102280_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT)","volume":"77","author":"Lemaitre","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.pupt.2023.102280_bib8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2023.102280_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jcph.2060","article-title":"Drug interactions with a short course of nirmatrelvir and ritonavir: prescribers and patients beware","volume":"62","author":"Ratain","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pupt.2023.102280_bib10","article-title":"Optimizing the use of nirmatrelvir\/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"year":"2023","series-title":"Management and Outcome of COVID-19 Infection Using Nirmatrelvir\/Ritonavir in Kidney Transplant Patients","author":"Gigu\u00e8re","key":"10.1016\/j.pupt.2023.102280_bib11"},{"key":"10.1016\/j.pupt.2023.102280_bib12","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants","volume":"22","author":"Lange","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.pupt.2023.102280_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2023.102280_bib15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"Badri","year":"2015","journal-title":"Am. J. Transplant."},{"year":"2022","series-title":"AST Statement on Oral Antiviral Therapy for COVID-19 for Organ Transplant Recipients","key":"10.1016\/j.pupt.2023.102280_bib16"},{"key":"10.1016\/j.pupt.2023.102280_bib17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.16997","article-title":"Effect of nirmatrelvir\/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients","volume":"22","author":"Wang","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib19","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/ajt.17140","article-title":"COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era","volume":"22","author":"Hedvat","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib20","first-page":"2356","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2, kidney","volume":"7","author":"Devresse","year":"2022","journal-title":"Int. Rep."},{"key":"10.1016\/j.pupt.2023.102280_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14037","article-title":"Saving lives with nirmatrelvir\/ritonavir one transplant patient at a time","author":"Belden","year":"2023","journal-title":"Transpl. Infect. Dis."},{"year":"2022","series-title":"Nirmatrelvir\/ritonavir Use with Tacrolimus in Lung Transplant Recipients: A Single-Center Case Series","author":"Dewey","key":"10.1016\/j.pupt.2023.102280_bib22"},{"key":"10.1016\/j.pupt.2023.102280_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/M22-0281","article-title":"Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions","volume":"175","author":"Marzolini","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2023.102280_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ajem.2023.04.045","article-title":"Tacrolimus toxicity due to enzyme inhibition from ritonavir","volume":"69","author":"Snee","year":"2023","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.pupt.2023.102280_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.pupt.2023.102280_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jcph.798","article-title":"CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects","volume":"57","author":"Zhu","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.pupt.2023.102280_bib27","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1093\/cid\/ciad159","article-title":"Complexity interactions between nirmatrelvir\/ritonavir and voriconazole in patients with coronavirus disease 2019","volume":"76","author":"Wang","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.pupt.2023.102280_bib28","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2023.102280_bib29","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/jac\/dkad144","article-title":"High-titer convalescent plasma plus nirmatrelvir\/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients","volume":"78","author":"Huygens","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2023.102280_bib30","first-page":"589","article-title":"Nirmatrelvir\/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients","volume":"35","author":"P\u00e9rez Catal\u00e1n","year":"2022","journal-title":"Rev. Espa\u00f1ola Quimioter."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:50Z","timestamp":1761082310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"alternative-id":["S1094553923000925"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102280","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of nirmatrelvir\/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102280"}}